- Potential benefitMay improve antibiotic stewardship and clinical care by identifying beneficiaries who are not truly allergic to penicil…
- Potential benefitCould reduce adverse health outcomes tied to penicillin allergy labels (e.g., longer hospital stays, higher perioperati…
- Potential benefitSupporters may cite potential long‑run Medicare savings from fewer complications, shorter hospital stays, and use of le…
PAVE Act
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The Penicillin Allergy Verification and Evaluation Act would amend the Social Security Act to add "penicillin allergy verification and evaluation" to the list of components for the Medicare initial preventive physical examination and the annual wellness visit. The bill defines the service to include identifying individuals with a reported penicillin allergy, assessing whether the history is consistent with an allergy, providing information about harms of an allergy label, and referring patients to allergy/immunology specialists as appropriate.
Extent of federal involvement: liberals and centrists accept adding this preventive element; conservatives worry about federal micromanagement of clinical practice.
Relative to its intended legislative type, this bill is a focused substantive policy change that is clear about the problem it targets and integrates directly into the Social Security Act to create a new defined Medicare-covered service; however, it provides limited operational, fiscal, and accountability detail.
The Penicillin Allergy Verification and Evaluation Act would amend the Social Security Act to add "penicillin allergy verification and evaluation" to the list of components for the Medicare initial preventive physical examination and the annual wellness visit.
The bill defines the service to include identifying individuals with a reported penicillin allergy, assessing whether the history is consistent with an allergy, providing information about harms of an allergy label, and referring patients to allergy/immunology specialists as appropriate.
It states that separate payment for structured penicillin allergy validation and evaluation on the same day as an exam or visit is not prohibited.
Content alone suggests a reasonably plausible path: the bill is narrow, technical, focused on patient safety and stewardship, and contains implementation-flexible language that tends to attract bipartisan support. However, uncertainty about Medicare cost impact, absence of explicit payment mechanics or offsets, and normal procedural hurdles (especially in the Senate and during budget review) reduce the likelihood relative to purely non-spending technical fixes.
Relative to its intended legislative type, this bill is a focused substantive policy change that is clear about the problem it targets and integrates directly into the Social Security Act to create a new defined Medicare-covered service; however, it provides limited operational, fiscal, and accountability detail.
Extent of federal involvement: liberals and centrists accept adding this preventive element; conservatives worry about federal micromanagement of clinical practice.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenMay increase near‑term Medicare expenditures by adding a required item to preventive visits and by increasing referrals…
- CitiesCould create access and capacity issues in areas with few allergists or immunologists, producing delays for beneficiari…
- Potential burdenAdds administrative and documentation requirements for clinicians and Medicare billing systems (coding, workflow change…
Why the argument around this bill splits.
Extent of federal involvement: liberals and centrists accept adding this preventive element; conservatives worry about federal micromanagement of clinical practice.
A mainstream liberal would likely view this bill positively as a targeted, evidence-based public health measure that can improve patient outcomes and strengthen antibiotic stewardship.
They would note the bill’s focus on delabeling incorrect penicillin allergies, which research shows can reduce use of broader-spectrum antibiotics, shorten hospital stays, and lower mortality.
They would see the referral requirement and allowance for separate payment as steps to ensure appropriate clinical follow-up.
A mainstream centrist would see the bill as a pragmatic, narrowly focused health-policy fix that addresses a documented clinical problem.
They would appreciate evidence cited in the bill that most self-reported penicillin allergies are incorrect and that evaluation can be cost-saving, while also flagging the need for a fiscal estimate and implementation details.
Centrists would favor modest, well-scoped changes to preventive care but want safeguards — such as CBO scoring, pilot programs, or monitoring — to ensure it is cost-effective and administrable.
A mainstream conservative would view the bill with cautious skepticism: supportive of efforts to improve clinical care and reduce inappropriate antibiotic use in principle, but concerned about adding new federally defined requirements to Medicare preventive visits and potential increases in taxpayer costs.
They would emphasize the need to avoid federal micromanagement of physician practice and to ensure no unfunded mandate or increased program spending without offsets.
They may prefer this to be optional guidance rather than a statutory addition or demand clearer fiscal neutrality and provider flexibility.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content alone suggests a reasonably plausible path: the bill is narrow, technical, focused on patient safety and stewardship, and contains implementation-flexible language that tends to attract bipartisan support. However, uncertainty about Medicare cost impact, absence of explicit payment mechanics or offsets, and normal procedural hurdles (especially in the Senate and during budget review) reduce the likelihood relative to purely non-spending technical fixes.
- No CBO/CMS cost estimate is included in the bill text; the net fiscal effect (short-term increased visits/referrals versus potential downstream savings) is unknown and will heavily influence committee and floor support.
- The bill permits 'separate payment' but does not specify payment mechanisms or rates; administrative implementation (coding, coverage determinations) could be contentious or slow.
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Extent of federal involvement: liberals and centrists accept adding this preventive element; conservatives worry about federal micromanagem…
Content alone suggests a reasonably plausible path: the bill is narrow, technical, focused on patient safety and stewardship, and contains…
Relative to its intended legislative type, this bill is a focused substantive policy change that is clear about the problem it targets and integrates directly into the Social Security Act to create a new defined Medicar…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.